Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Available 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Mantle-Cell 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma 1

Interventions

Cyclophosphamide 35fludarabine 18Methotrexate 17fludarabine phosphate 16Dexamethasone 16blinatumomab 15Vincristine 15Cytarabine 14Melphalan 12Tacrolimus 11Etoposide 11pegaspargase 10Whole-Body Irradiation 9Mercaptopurine 9Calcium Dobesilate 9merphos 8Dasatinib 8Busulfan 8Asparaginase 8Thiotepa 7Prednisone 7Mycophenolic Acid 7Leucovorin 7Granulocyte Colony-Stimulating Factor 7Doxorubicin 7prednylidene 6ponatinib 6calaspargase pegol 6Stem Cell Transplantation 6Specimen Handling 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Precursor Cell Lymphoblastic Leukemia-Lymphoma × brexucabtagene autoleucel × Clear all
NCT03642626 2026-01-23

MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Masonic Cancer Center, University of Minnesota

Phase 2 Active not recruiting
150 enrolled 23 charts
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡